Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1964 Apr;43(4):681–695. doi: 10.1172/JCI104953

Abnormal Plasminogen-Plasmin System Activity (Fibrinolysis) in Patients with Hepatic Cirrhosis: Its Cause and Consequences*

Anthony P Fletcher 1, Oliver Biederman 1, Don Moore 1, Norma Alkjaersig 1, Sol Sherry 1
PMCID: PMC289545  PMID: 14149921

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization. J Clin Invest. 1962 Apr;41:917–934. doi: 10.1172/JCI104547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. doi: 10.1172/JCI103885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BANG N. U., FLETCHER A. P., ALKJAERSIG N., SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy. J Clin Invest. 1962 Apr;41:935–948. doi: 10.1172/JCI104548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BLIX S. The proactivator of the fibrinolytic system in human plasma. The quantitative determination and its clinical application. Acta Med Scand. 1962 Jan;171:83–98. doi: 10.1111/j.0954-6820.1962.tb04170.x. [DOI] [PubMed] [Google Scholar]
  5. FINKBINER R. B., McGOVERN J. J., GOLDSTEIN R., BUNKER J. P. Coagulation defects in liver disease and response to transfusion during surgery. Am J Med. 1959 Feb;26(2):199–213. doi: 10.1016/0002-9343(59)90309-2. [DOI] [PubMed] [Google Scholar]
  6. FLETCHER A. P., ALKJAERSIG N., SHERRY S. Fibrinolytic mechanisms and the development of thrombolytic therapy. Am J Med. 1962 Nov;33:738–752. doi: 10.1016/0002-9343(62)90251-6. [DOI] [PubMed] [Google Scholar]
  7. FLETCHER A. P., ALKJAERSIG N., SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest. 1962 Apr;41:896–916. doi: 10.1172/JCI104546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. FLETCHER A. P., ALKJAERSIG N., SHERRY S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest. 1958 Sep;37(9):1306–1315. doi: 10.1172/JCI103719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. FLETCHER A. P., ALKJAERSIG N., SHERRY S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest. 1959 Jul;38(7):1096–1110. doi: 10.1172/JCI103886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. GENTON E., KERN F., Jr, VON KAULLA K. Fibrinolysis induced by pressor amines. Am J Med. 1961 Oct;31:564–571. doi: 10.1016/0002-9343(61)90140-1. [DOI] [PubMed] [Google Scholar]
  11. GROSSI C. E., MORENO A. H., ROUSSELOT L. M. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon amino caproic acid. Ann Surg. 1961 Mar;153:383–393. doi: 10.1097/00000658-196103000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. GROSSI C. E., ROUSSELOT L. M., PANKE W. F. Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunts. Am J Surg. 1962 Oct;104:512–526. doi: 10.1016/0002-9610(62)90387-2. [DOI] [PubMed] [Google Scholar]
  13. KWAAN H. C., LO R., MCFADZEAN A. J. Antifibrinolytic activity in primary carcinoma of the liver. Clin Sci. 1959 May;18:251–261. [PubMed] [Google Scholar]
  14. KWAAN H. C., MCFADZEAN A. J., COOK J. On plasma fibrinolytic activity in cryptogenetic splenomegaly. Scott Med J. 1957 Apr;2(4):137–150. doi: 10.1177/003693305700200402. [DOI] [PubMed] [Google Scholar]
  15. KWAAN H. C., MCFADZEAN A. J., COOK J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet. 1956 Jan 21;270(6908):132–136. doi: 10.1016/s0140-6736(56)91093-5. [DOI] [PubMed] [Google Scholar]
  16. LATALLO Z. S., FLETCHER A. P., ALKJAERSIG N., SHERRY S. Inhibition of fibrin polymerization by fibrinogen proteolysis products. Am J Physiol. 1962 Apr;202:681–686. doi: 10.1152/ajplegacy.1962.202.4.681. [DOI] [PubMed] [Google Scholar]
  17. NAKAMURA T., NAKAMURA S., KANEKO T., SUZUKI T., TOKITA K., ABE S. Measurement of extrahepatic shunted blood flow in liver cirrhosis. J Lab Clin Med. 1962 Dec;60:889–901. [PubMed] [Google Scholar]
  18. NIEWIAROWSKI S., KOWALSKI E. Unnouvel anticoagulant dérivé du fibrinogène. Rev Hematol. 1958 Jul-Sep;13(3):320–328. [PubMed] [Google Scholar]
  19. PURCELL G., Jr, PHILLIPS L. L. FIBRINOLYTIC ACTIVITY IN CIRRHOSIS OF THE LIVER. Surg Gynecol Obstet. 1963 Aug;117:139–144. [PubMed] [Google Scholar]
  20. RAPAPORT S. I., AMES S. B., MIKKELSEN S., GOODMAN J. R. Plasma clotting factors in chronic hepatocellular disease. N Engl J Med. 1960 Aug 11;263:278–282. doi: 10.1056/NEJM196008112630604. [DOI] [PubMed] [Google Scholar]
  21. RATNOFF O. D. An accelerating property of plasma for the coagulation of fibrinogen by thrombin. J Clin Invest. 1954 Aug;33(8):1175–1182. doi: 10.1172/JCI102990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. SAWYER W. D., ALKJAERSIG N., FLECTCHER A. P., SHERRY S. A comparison of the fibrinolytic and fibrinogenolytic effects of plasminogen activators and proteolytic enzymes in plasma. Thromb Diath Haemorrh. 1960 Dec 15;5:149–161. [PubMed] [Google Scholar]
  23. SAWYER W. D., FLETCHER A. P., ALKJAERSIN N., SHERRY S. Studies on the thrombolytic activity of human plasma. J Clin Invest. 1960 Feb;39:426–434. doi: 10.1172/JCI104054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. SHERRY S., FLETCHER A. P., ALKJAERSIG N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev. 1959 Apr;39(2):343–382. doi: 10.1152/physrev.1959.39.2.343. [DOI] [PubMed] [Google Scholar]
  25. SHERRY S., LINDEMEYER R. I., FLETCHER A. P., ALKJAERSIG N. Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959 May;38(5):810–822. doi: 10.1172/JCI103863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. TRIANTAPHYLLOPOULOS D. C. Effects of intravenous injections of the anticoagulant fraction of incubated fibrinogen on blood coagulation. Can J Biochem Physiol. 1960 Aug;38:909–918. [PubMed] [Google Scholar]
  27. WEINER M., DE CRINIS K., REDISCH W., STEELE J. M. Influence of some vasoactive drugs on fibrinolytic activity. Circulation. 1959 Jun;19(6):845–848. doi: 10.1161/01.cir.19.6.845. [DOI] [PubMed] [Google Scholar]
  28. WEINER M. THE FIBRINOLYTIC RESPONSE TO NICOTINIC ACID IN ABNORMAL LIVER STATES. Am J Med Sci. 1963 Sep;246:294–300. doi: 10.1097/00000441-196309000-00006. [DOI] [PubMed] [Google Scholar]
  29. ZETTERQVIST E., von FRANCKEN Coagluation disturbances with manifest bleeding in extrahepatic portal hypertension and in liver cirrhosis. Preliminary results of heparin treatment. Acta Med Scand. 1963 Jun;173:753–760. [PubMed] [Google Scholar]
  30. ZUCKER M. B., SIEGEL M., CLIFFTON E. E., BELLVILLE J. W., HOWLAND W. S., GROSSI C. E. Generalized excessive oozing in patients undergoing major surgery and receiving multiple blood transfusions. J Lab Clin Med. 1957 Dec;50(6):849–861. [PubMed] [Google Scholar]
  31. ZUCKER M. B., SIEGEL M., CLIFFTON E. E., BELLVILLE J. W., HOWLAND W. S., GROSSI C. E. The effect of hepatic lobectomy on some blood clotting factors and on fibrinolysis. Ann Surg. 1957 Nov;146(5):772–781. doi: 10.1097/00000658-195711000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES